147 related articles for article (PubMed ID: 25169742)
21. MiR-363 suppresses cell migration, invasion, and epithelial-mesenchymal transition of osteosarcoma by binding to NOB1.
Zhang Y; Wang F; Wang L; Zhang Q
World J Surg Oncol; 2020 May; 18(1):83. PubMed ID: 32357945
[TBL] [Abstract][Full Text] [Related]
22. Lentivirus-mediated knockdown of NOB1 suppresses the proliferation of colon cancer cells.
Liu Y; Huang H; Yuan B; Zhuang LY; Luo TP; Zhang Q
Z Gastroenterol; 2014 May; 52(5):429-35. PubMed ID: 24824907
[TBL] [Abstract][Full Text] [Related]
23. In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression.
Liu CM; Hsieh CL; He YC; Lo SJ; Liang JA; Hsieh TF; Josson S; Chung LW; Hung MC; Sung SY
PLoS One; 2013; 8(1):e53795. PubMed ID: 23342005
[TBL] [Abstract][Full Text] [Related]
24. Anticancer activity of NOB1-targeted shRNA combination with TRAIL in epithelial ovarian cancer cells.
Lin Y; Xu T; Teng H; Cui M
Int J Clin Exp Pathol; 2015; 8(9):10061-71. PubMed ID: 26617713
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-326 functions as a tumor suppressor in colorectal cancer by targeting the nin one binding protein.
Wu L; Hui H; Wang LJ; Wang H; Liu QF; Han SX
Oncol Rep; 2015 May; 33(5):2309-18. PubMed ID: 25760058
[TBL] [Abstract][Full Text] [Related]
26. MYO6 knockdown inhibits the growth and induces the apoptosis of prostate cancer cells by decreasing the phosphorylation of ERK1/2 and PRAS40.
Wang D; Zhu L; Liao M; Zeng T; Zhuo W; Yang S; Wu W
Oncol Rep; 2016 Sep; 36(3):1285-92. PubMed ID: 27431378
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
28. miR‑145 inhibits human non‑small-cell lung cancer growth by dual-targeting RIOK2 and NOB1.
Liu K; Chen H; You Q; Ye Q; Wang F; Wang S; Zhang S; Yu K; Li W; Gu M
Int J Oncol; 2018 Jul; 53(1):257-265. PubMed ID: 29749434
[TBL] [Abstract][Full Text] [Related]
29. RNF7 knockdown inhibits prostate cancer tumorigenesis by inactivation of ERK1/2 pathway.
Xiao Y; Jiang Y; Song H; Liang T; Li Y; Yan D; Fu Q; Li Z
Sci Rep; 2017 Mar; 7():43683. PubMed ID: 28252001
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of NOB1 by microRNA-330-5p overexpression represses cell growth of non-small cell lung cancer.
Kong R; Liu W; Guo Y; Feng J; Cheng C; Zhang X; Ma Y; Li S; Jiang J; Zhang J; Qiao Z; Qin J; Lu T; He X
Oncol Rep; 2017 Oct; 38(4):2572-2580. PubMed ID: 28849232
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can inhibit the in vitro and in vivo proliferation of prostate cancer cells.
Jiang N; Zhou LQ; Zhang XY
Asian J Androl; 2010 Sep; 12(5):709-17. PubMed ID: 20531280
[TBL] [Abstract][Full Text] [Related]
32. Nin one binding protein expression as a prognostic marker in prostate carcinoma.
Liu G; Shen D; Jiao L; Sun Y
Clin Transl Oncol; 2014 Sep; 16(9):843-7. PubMed ID: 24493285
[TBL] [Abstract][Full Text] [Related]
33. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
Liu R; Sun J; Zhang Z; Xu Y
Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
[TBL] [Abstract][Full Text] [Related]
34. MTSS1 hypermethylation is associated with prostate cancer progression.
Chen J; Huang L; Zhu Q; Wang Z; Tang Z
J Cell Physiol; 2020 Mar; 235(3):2687-2697. PubMed ID: 31541465
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-612 inhibits cervical cancer progression by targeting NOB1.
Jin Y; Zhou X; Yao X; Zhang Z; Cui M; Lin Y
J Cell Mol Med; 2020 Mar; 24(5):3149-3156. PubMed ID: 31970934
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression.
Shukla S; Sharma H; Abbas A; MacLennan GT; Fu P; Danielpour D; Gupta S
PLoS One; 2013; 8(1):e53527. PubMed ID: 23308245
[TBL] [Abstract][Full Text] [Related]
37. Silencing KRAS overexpression in arsenic-transformed prostate epithelial and stem cells partially mitigates malignant phenotype.
Ngalame NN; Tokar EJ; Person RJ; Waalkes MP
Toxicol Sci; 2014 Dec; 142(2):489-96. PubMed ID: 25273566
[TBL] [Abstract][Full Text] [Related]
38. Suppression of MED19 expression by shRNA induces inhibition of cell proliferation and tumorigenesis in human prostate cancer cells.
Cui X; Xu D; Lv C; Qu F; He J; Chen M; Liu Y; Gao Y; Che J; Yao Y; Yu H
BMB Rep; 2011 Aug; 44(8):547-52. PubMed ID: 21871180
[TBL] [Abstract][Full Text] [Related]
39. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
Kong Q; Chen XS; Tian T; Xia XY; Xu P
Oncol Rep; 2017 Feb; 37(2):803-812. PubMed ID: 27959429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
